Resumption/efficacy and safety of an azithromycin-containing regimen against Mycobacterium avium complex lung disease in patients who experienced adverse effects with a clarithromycin-containing regimen
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Respiratory Investigation
- Vol. 59 (2) , 212-217
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Intermittent Antibiotic Therapy for Nodular Bronchiectatic Mycobacterium avium Complex Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Macrolide/Azalide Therapy for Nodular/Bronchiectatic Mycobacterium avium Complex Lung DiseaseChest, 2014
- Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infectionsInternational Journal of Antimicrobial Agents, 2013
- The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium avium Complex Disease TreatmentAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Prognostic Factors of 634 HIV-Negative Patients with Mycobacterium avium Complex Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year periodJournal of Infection and Chemotherapy, 2012
- An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial DiseasesAmerican Journal of Respiratory and Critical Care Medicine, 2007
- A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex diseaseRespiratory Medicine, 2007
- Antibacterial macrolides: a drug class with a complex pharmacological profilePharmacological Research, 2004
- Susceptibility Testing for MycobacteriaClinical Infectious Diseases, 2000